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ABSTRACT: Cucumbers have been anecdotally claimed to have
anti-inflammatory activity for a long time, but the active principle
was not identified. idoBR1, (2R,3R,4R,5S)-3,4,5-trihydroxypiper-
idine-2-carboxylic acid, is an iminosugar amino acid isolated from
fruits of certain cucumbers, Cucumis sativus (Cucurbitaceae). It has
no chromophore and analytically behaves like an amino acid
making detection and identification difficult. It has anti-
inflammatory activity reducing lipopolysaccharide (LPS)-induced
tumor necrosis factor alpha (TNF-α) in THP-1 cells and ex vivo
human blood. It showed selective inhibition of human α-L-
iduronidase and sialidases from both bacteria (Tannerella forsythia)
and human THP-1 cells. idoBR1 and cucumber extract reduced
the binding of hyaluronic acid (HA) to CD44 in LPS-stimulated
THP-1 cells and may function as an anti-inflammatory agent by inhibiting induced sialidase involved in the production of
functionally active HA adhesive CD44. Similar to the related iminosugars, idoBR1 is excreted unchanged in urine following
consumption. Its importance in the diet should be further evaluated.
■ INTRODUCTION
Cucumber (Cucumis sativus) is a widely cultivated plant in the
gourd family Cucurbitaceae, which includes squash. Cucum-
bers probably originated in India and have been cultivated for
at least 3000 years in Western Asia1 and probably introduced
to other parts of Europe by the Romans.2 Records of cucumber
cultivation appear in France in the 9th century, in England in
the 14th century, and in North America by the mid-16th
century.
Cucumbers and cucumber extracts have long been
recognized as having anti-inflammatory properties and have
been used topically for various types of skin problems,
including swelling under the eyes and sunburns.3 Cucumber
was very popular in the ancient civilizations of Egypt, Greece,
and Rome, where it was used not only as a food but also for its
skin-healing properties. It has long been recognized by women
for benefits to red, tired, and puffy eyes. There are a number of
reports of the anti-inflammatory activity of cucumber aqueous
extracts, but the active components were not identified;4,5 a
recent report identified an amino acid fraction as reducing
angiotensin II-induced inflammation in human endothelial
cells, but only common amino acids could be identified by the
liquid chromatography−mass spectrometry (LCMS) method
used.6 Certain varieties of cucumber have been shown to
contain a single iminosugar amino acid, (2R,3R,4R,5S)-3,4,5-
trihydroxypiperidine-2-carboxylic acid (idoBR1), a trihydrox-
ypipecolic acid (1) (Figure 1).7 While many iminosugars have
been isolated from plants, BR1 (2S,3R,4R,5S)-3,4,5-trihydrox-
ypiperidine-2-carboxylic acid (2) from Baphia racemosa8,9 is
one of the very few iminosugar acids that have been identified
as a natural product.10 Iminosugar acids are much more
difficult to isolate and identify than their iminosugar analogues
because of the high content of acidic and neutral amino acids
in plants. idoBR1 was synthesized before it was isolated.11
idoBR1 is reported to have anti-inflammatory activity, and
cucumber extract containing idoBR1 has shown benefits in
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Figure 1. Structures of iminosugar acids idoBR1 (1), BR1 (2), and
equivalent iminosugar DNJ (3).
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osteo-arthritis7,12 without signs of toxicity.13 In the present
study, we sought to investigate the anti-inflammatory effects
and possible mechanism for idoBR1 and a cucumber extract
standardized for the idoBR1 content, Q-actin. BR1 is reported
to be a glycosidase inhibitor,8 and for the possible mechanism,
we decided to focus on glycosidase activity of idoBR1 and, in
particular, specific properties/signaling pathways that might be
related to the structural similarity of uronic acids.
■ MATERIALS AND METHODS
Chemicals. idoBR1 was synthesized11 (MI164687 pur-
chased from Carbosynth Limited, Compton, UK). Q-actin
idoBR1-standardized cucumber extract (batch no. B17CF007)
was obtained from IminoTech Inc, Carson City, Nevada, USA.
BR1, 1-deoxynojirimycin (DNJ), and castanospermine were
authentic samples from PhytoQuest Limited, Aberystwyth,
Iminosugar library. Dexamethasone (DM) and mifepristone
were from Sigma-Aldrich.
Gas Chromatography−Mass Spectrometry. Gas chro-
matography (GC) was found to give better resolution of
idoBR1 in extracts than HPLC and allowed easier
quantification. Castanospermine was added to the dissolved
cucumber extract at 0.2 mg per g to act as an internal reference.
Samples (0.1 mg) of dried cucumber extract or pure
compounds were reacted with 30 μL of Pierce TriSil reagent;
after 20 min, the trimethylsilylated (TMS) compounds were
analyzed on a Perkin Elmer Turbomass spectrometer using a
high-polarity fused-silica column (Varian “Factor Four” VF-
5ms column, 25 m × 0.25 mm i.d., 0.25 μm phase thickness).
The carrier gas (helium) flow rate was 1 mL/min. The TMS
derivatives were separated using a temperature program
starting at 160 °C for 5 min, followed by a linear increase to
300 °C at a rate of 10 °C/min. Electron impact mass
spectrometry (MS) of the column eluent was carried out with
the quadrupole ion filter system run at 250 °C constantly
during analysis.
TNF-α ELISA on Human Blood. Whole blood was
supplied by the Scottish National Blood Transfusion Service
(SNBTS), Glasgow, UK, and was preincubated for 48 h with
varying concentrations of Q-actin or idoBR1, after which
lipopolysaccharide (LPS) (10 μg/mL) was added, and
incubations continued for a further 20 h. Following incubation
at 37 °C (5% CO2, 100% humidity), plasma was collected from
the blood by centrifugation (30 s 10,000 g), and the levels of
tumor necrosis factor alpha (TNF-α) in plasma samples were
measured by enzyme-linked immunosorbent assay (ELISA).
Values represent the mean ± sd of n = 3.
Statistical Analysis. All statistical analyses were performed
with GraphPad Prism. Significance is denoted as *(p = ≤0.05).
Effect of Mifepristone on the idoBR1- and DM-
Induced Suppression of LPS-Stimulated TNF-α Produc-
tion from Human THP-1 Cells. Cells were preincubated
with mifepristone alone (50 and 100 μM), mifepristone and
idoBR1 (10 μM), or mifepristone and 50 μM DM for 24 h and
then incubated for a further 20 h in the absence or presence of
LPS (10 μg/mL). Following incubation at 37 °C (5% CO2,
100% humidity), the medium was collected from each culture
well, and the levels of TNF-α were measured by ELISA. In
order to preclude the possibility that the suppressive effect of
idoBR1 may have been mediated via increased cell death, the
effect of idoBR1 (10 μM) was assessed on cell viability by two
methods: (a) enumeration of nonviable cells by Trypan blue
uptake and (b) by MTT dye conversion. Following incubation,
Trypan blue was added to cells immediately before counting
(using a hemocytometer), and the percentage of blue cells was
subtracted from the total cell count. For MTT dye conversion,
following incubation, 50 μL of the medium was removed from
all wells and replaced with 50 μL of 4 mg/mL MTT (Sigma)
in sterile PBS. Cells were incubated at 37 °C for further 4 h,
and then, 100 μL of DMSO was added to each well, and
absorbances were measured at 570 nm (SpectraMax Micro-
plate Reader, Molecular Devices).
Serum Cytokine Study in Healthy Humans Given
Cucumber Extract. Serum cytokines were measured over 4
days in healthy human subjects (white caucasian male, mean
weight 73 kg, and ages 20−25) pre- and post-intense exercise
[placebo n = 7 and cucumber extract (Q-actin) treated n = 10].
The subjects were given Q-actin (20 mg) or placebo in
capsules daily, including before the first exercise. Venous blood
samples were collected prior to the exercise and on days 1, 2, 3,
and 4 post-muscle damage using the standard phlebotomy
technique from an antecubital vein. Blood was collected into a
serum separator tube and allowed to clot. Once clotted, the
blood was centrifuged (1500g for 20 min). The isolated serum
was frozen at −80 °C until cytokine analysis. Serum
concentrations of TNF-α, IL-10, and IL-12p70 were measured
using a multiplex technique.14 Briefly, aliquots of the serum
were analyzed in duplicates using a high-sensitivity bead-based
multiplex assay, according to the manufacturer’s recommen-
dations (MILLIPLEX; EMD Millipore; St. Louis, MO).
Glycosidase Activity Assay. BR1 is reported to be an
inhibitor of iduronidase.8 BR1 and idoBR1 also have some
structural features suggesting that they may be analogues of
sialic acids. We, therefore, assayed BR1, idoBR1, and the
related DNJ in a panel of glycosidases to determine the
selectivity of inhibition. For the α-L-iduronidase assay,
solutions of 0.2 M sodium formate buffer at pH 3.5 and 0.2
mM substrate 4-methylumbelliferyl-α-L-iduronide (Glyco-
synth, 44076), dissolved in buffer, were prepared. A solution
of recombinant human α-L-iduronidase (IDUA, R&D Systems,
4119-GH) was also prepared at between 0.8 μg/mL in the
buffer. The incubation mixture consisted of 10 μL of enzyme
solution, 10 μL of 1 mg/mL aqueous idoBR1 and BR1
solution, and 20 μL of 0.2 mM substrate made up in buffer at
pH 3.5. The reactions were carried out at 27 °C and stopped
by removing a 10 μL aliquot and adding it to 200 μL of 0.5 M
glycine (pH 10.4) in a black-well plate during the exponential
phase of the reaction, which had been determined at the
beginning using uninhibited assays in which water was replaced
by an inhibitor. Final fluorescence values were read at
excitation and emission wavelengths of 365 and 445 nm,
respectively, using a SpectraMax microplate reader (Molecular
Devices). Assays were carried out in triplicates. Results were
expressed as a percentage of uninhibited assays in which water
was replaced by an inhibitor.
Sialidase assays used 10 μL of 1 mg/mL idoBR1 (or water
without an inhibitor) and 10 μL of 2.5 nM sialidase (NanH
from Tannerella forsythiaa broad specificity GH33 bacterial
enzyme) incubated in the presence of 30 μL of 0.1 mM
methyl-umbeliferyl-N-acetyl-neuraminic acid, pH 7.2, in 20
mM sodium phosphate buffer.15 Oseltamivir was used as a
positive control. Reactions were stopped at 60, 120, and 180 s
using 100 μL of 100 mM sodium carbonate buffer, pH 10.5,
added to 50 μL of the reaction mixture. Release of methyl-
umbelliferone was quantified by measuring fluorescence
emission at 450 nm and excitation at 350 nm. Reactions
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were carried out in triplicates. The percentage of sialidase
activity was expressed as the change in fluorescence compared
to that of a reaction without inhibitors.
Other glycosidase assays used p-nitrophenyl-glycopyrano-
sides and were carried out using the iminosugar acids idoBR1
and BR1 as available, and the results are compared with the
related iminosugar DNJ (3). All enzymes and p-nitrophenyl-
substrates were purchased from Sigma, with the exception of β-
mannosidase which was obtained from Megazyme. Enzyme
reactions were carried out at 27 °C in 0.1 M citric acid/0.2 M
disodium hydrogen phosphate buffers at the optimum pH for
the enzyme. The incubation mixture consisted of 10 μL of
enzyme solution, 10 μL of 1 mg/mL aqueous solution of the
extract, and 50 μL of the appropriate 5 mM p-nitrophenyl
substrate made up in buffer at the optimum pH for the
enzyme. The reactions were stopped by the addition of 70 μL
of 0.4 M glycine (pH 10.4) during the exponential phase of the
reaction. This phase had been determined at the beginning
using uninhibited assays in which water was replaced by an
inhibitor. Final absorbances were measured at 405 nm using a
VersaMax microplate reader (molecular devices). Assays were
carried out in triplicates, and the values given are means of the
three replicates per assay. Results were expressed as %
inhibition compared to the controls without inhibitors.
Cell Culture Sialidase Activity Assay. There can be
differences in enzymes from different sources, and so we
wanted to study human-derived as well as bacterial sialidases.
As the human sialidase enzymes are not readily commercially
available, we used activities from cell cultures.
THP-1 Cell Line Treatment for the Sialidase Activity Test.
The THP-1 cells were cultured in Roswell Park Memorial
Institute (RPMI) 1640 media supplemented with 10% FCS,
2β-mercaptoethanol, and glutamine to get 80% confluence in
culture flasks. The culture was aspirated and centrifuged at
1500 rpm for 5 min, and then, the pellet was resuspended in 1
mL of RPMI complete media and counted conventionally
using a hemocytometer. The cells (5 × 106) were incubated
with PMA (10 ng/mL) in separate dishes (stimulates the PKC
pathway) to form differentiated adherent macrophages. To
determine the sialidase activity, the adherent cells were
pretreated for 1 h with idoBR1 and Q-actin extracts, at the
concentrations 100 to 12.5 and 200 to 25 μg/mL respectively
serial diluted twofold, and DM at 100 and 1000 ng/mL as a
positive control followed by 24 h LPS (1 μg/mL) stimulation.
Post incubation, the cells were carried over to determine the
sialidase activity. The sialidase activity was found to be
maximum at the 16 h incubation time point with LPS.
Determination of Endogenous Sialidase Activity. THP-1
cells were washed with phosphate-buffered saline and
resuspended in ice-cold buffer containing 0.25 M sucrose, 1
mM EDTA, and 0.2 mM phenylmethylsulfonyl fluoride. The
cell suspension was sonicated on ice for 15 s on a low setting
(6% amplitude) (VibraCell; Sonics and Materials Inc.,
Newtown, CT) followed by centrifugation at 25,000g for 15
min at 4 °C. The resultant supernatant was used to determine
the lysosomal sialidase activity. Protein quantification of the
supernatant was performed using the Bio-Rad protein
determination kit as described above. For the determination
of lysosomal sialidase activity, 200 μg of the total protein was
mixed with 40 nmol 4-methyl-umbelliferyl-α-N-acetyl-D-
neuraminic acid (Sigma), the lysosomal sialidase-specific
substrate, 10 μmol sodium acetate buffer, pH 4.6, and 200
μg of bovine serum albumin in a total volume of 200 μL. The
sialidase reaction was allowed to proceed for 1 h at 37 °C and
was terminated by the addition of 0.25 M glycine NaOH, pH
10.4. The released 4-methyl-umbelliferyl-N-acetyl-D-neura-
minic acid was measured as fluorescence (Synergy 2
multimode microplate reader) at an excitation wavelength of
365 nm and an emission wavelength of 448 nm.
ELISA of Cytokines Produced by THP-1 Monocytic
Cell-Derived Macrophages. Sample Preparation for ELISA.
The cells were aspirated from an 80% confluence culture flask
and centrifuged at 1500 rpm for 5 min. The cell pellet was then
resuspended in 1 mL of RPMI complete media, and 1 × 105
cells were seeded to each well of a 96-well microtiter plate.
After 24 h incubation, PMA (10 ng/mL) was added to the 96-
well plate to differentiate the THP-1 cells. To determine the
range of cytokine production, the differentiated adherent THP-
1 cells (macrophages) were pretreated for 1 h with idoBR1 and
Q-actin extract at the concentrations 200 to 25 μg/mL diluted
twofold serially, followed by 2 h LPS (100 ng/mL) stimulation,
as reported by others using similarly differentiated THP-1
cells16 and also because trials showed measurable cytokines
and we were mainly interested in the signaling pathways here.
Post incubation, the cell supernatant from each of the wells
was aspirated into sterile microcentrifuge tubes and centrifuged
at 1000 rpm for 2−3 min to settle any cells present. The cell
supernatant was then used for evaluation of the presence of
TNF-α and other selected cytokines using ELISA.
Sandwich ELISA. ELISA plates coated with antibodies for
TNF-α, IL-12, IL-1β, IL-1α, or IL-10 (R&D Systems, USA)
were used following the manufacturer’s instructions. Optical
density (OD) was measured within 30 min after adding the
stop solution at 450 nm.
Determination of CD44-Bound HA Using Modified ELISA.
The anti-CD44 monoclonal antibody (Invitrogen, 2 μg) was
coated to each well in 96-well plates in 50 mM carbonate/
bicarbonate buffer (pH 9.6) and incubated overnight at 4 °C.
The unbound antibodies were washed out using PBS with
0.05% Tween 20 (PBST wash solution). The wells were
blocked using 1% BSA and incubated for 1 h at 37 °C. The
wells were washed thoroughly three times using PBST wash
solution by adding 200 μL into the wells. Cell lysates (50 μL)
were added to the wells, and plates were incubated for 1 h at
37 °C. The wells were then washed three times by adding 200
μL of PBST and soaking the wells for 30 s. The biotinylated-
hyaluronic acid (HA) antibody followed by streptavidin-HRP
was added to form an immune complex, and after incubating
for 60 min at 37 °C, the solution was aspirated, and the wells
were washed thrice with 200 μL of the wash solution by
soaking the wells for 30 s. Both chromogen A and chromogen
B (50 μL each) were added to each well. The plate was
incubated for 15 min in the dark at 37 °C. The reaction was
stopped by adding 50 μL of the stop solution, and absorbance
was read at 450 nm.
MAPK Signaling Effects of idoBR1 and Cucumber
Extract Containing idoBR1. THP-1 cells were cultured in
RPMI media supplemented with mercaptoethanol and
glutamine to get 80% confluence in culture flasks; they were
then aspirated and centrifuged at 1500 rpm for 5 min. The cell
pellet was resuspended in 1 mL of RPMI complete media and
counted conventionally using a hemocytometer. The cells (5 ×
106) were incubated with PMA (10 ng/mL) in separate dishes
to differentiate THP-1 cells into adherent macrophages. To
determine the protein expression p38 and p42/44, the
adherent cells were pretreated for 1 h with idoBR1100
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and 50 μg/mLand Q-actin extract200 and 100 μg/mL
followed by 2 h LPS (1 μg/mL) stimulation. DM was used as a
positive control. Post incubation, the cells were harvested, and
the whole protein was isolated.
Western Blot Procedure. Cell pellets were lysed, and the
protein concentration was determined using the Bio-Rad
protein determination assay (Bio-Rad). Total cell proteins
were subjected to 8% polyacrylamide SDS gel electrophoresis
followed by transferring onto polyvinylidene difluoride
membranes (Thermo Scientific). The membranes were probed
with either mouse anti-phospho-p38 mAb (Thermo Scientific)
or mouse anti-phospho-p42/44 mAb (Thermo Scientific),
followed by horseradish peroxidase-conjugated goat anti-
mouse polyclonal antibodies (Thermo Scientific). All
immunoblots were visualized by ECLTM Western Blotting
Reagent (Amersham Biosciences).
Oral Consumption and Excretion of idoBR1. Q-actin
(1.0 g) was dissolved in water and drunk with sliced tomato at
mid-day by one adult white male (60, BMI 19) and one female
(52, BMI 17.5). The healthy volunteers ate no other Cucurbits
for 15 h prior to the experiment. Urine samples before
consumption were collected over 3 h as t = 0, and then,
samples were collected for 9 h for the female and 15 h for the
male. Q-actin (0.5 g) was extracted in water for 15 h, 100 μL of
1 mg/mL castanospermine was added as an internal reference,
and the idoBR1 content was calculated as 1.4% by GCMS after
cation exchange (Amberlite IR120 H+) chromatography. Each
person, therefore, consumed 14 mg of idoBR1. The entire
urine samples were similarly treated using an excess of cation
exchange resin, except the material displaced by ammonia
solution was run a second time through the same cation
exchange resin (now in the ammonium form) to reduce strong
bases (which bind to IR120 resin in the ammonium form), and
only the unretained material was kept. The urine idoBR1
fractions were dried and made up to 20 mL in water. Then 500
μL of each was sampled, and 25 μg of castanospermine added.
■ RESULTS AND DISCUSSION
To identify specific compounds in cucumber that could be
used as dietary supplements to reduce inflammation, we began
by chemically fractionating the extract from the cucumber C.
sativus. We identified the iminosugar acid idoBR1 (1) in the
extract by comparison with an authentic synthetic material.11
As described here, the purified compound and extract
containing it showed an inhibition of TNF-α production in
human blood and cultured THP-1 cells. idoBR1 is the C5
epimer of the iminosugar acid BR1 (2), related to the
iminosugar DNJ (3). DNJ is perhaps the most commonly
occurring natural iminosugar and a potent inhibitor of
glucosidases; it is currently used as the basis of a therapeutic
agent in Miglitol and Miglustat for diabetes and type I
Gaucher’s disease, respectively.17 BR1 is the corresponding
amino acid of DNJ; BR1, unlike DNJ, is not a strong inhibitor
of any glycosidase but has, nonetheless, been shown to have
potential for use in control of diabetes.18 GCMS analysis of
cucumber extract as a TMS mixture shows idoBR1 as the
component at 10.53 min retention time (Figure 2); it has a
distinctive mass spectrum with major fragments at 217
(100%), 258 (50%), 348 (25%), 375 (10%), and 450 (5%)
amu. BR1 gives a similar mass spectrum with a retention time
of 11.13 min under the same conditions. A second per-
trimethylsilyl derivative of idoBR1 with a major fragment at
420 amu is always seen at 20 s longer retention time but is
never observed with BR1. Other peaks in the spectra are other
molecules in the cucumber extract including sugars and amino
acids. Cucumber does not always contain idoBR1 and is
unusual among iminosugar-producing plants19 that it only
accumulates the single iminosugar amino acid and no
iminosugars. The Q-actin extract used in the biological studies
described here contained 1.4% idoBR1 (w/w) as determined
with an internal reference (castanospermine, retention time
11.98 min). Although not found to be straight forward for
quantification in extracts, LCMS using a triple quadrupole
mass spectrometer and electrospray ionization (ESI) (Thermo
Figure 2. GCMS chromatogram of cucumber extract (TMS) showing idoBR1 at 10.53 min.
Figure 3. idoBR1 reduces TNF-α levels in LPS-stimulated human plasma.
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Scientific) gave 178.01 m/z positive mode and 176.01 m/z
negative mode for idoBR1.
Evaluation of the Anti-Inflammatory Effects of
idoBR1 and Q-Actin in Human Blood. TNF-α, one of
the most important proinflammatory cytokines, is secreted
mainly from activated monocytes/macrophages in response to
diverse extracellular stimuli and plays a major role in acute and
chronic inflammatory diseases including septic shock and
rheumatoid arthritis,20 respectively. We tested whether treat-
ment of human blood with idoBR1 and Q-actin could reduce
the production of the inflammatory cytokine TNF-α upon LPS
stimulation. Indeed, when blood was incubated with
compounds or extracts for 48 h prior to LPS stimulation,
there were dose-dependent significant reductions in TNF-α
release (Figure 3). These data suggest that idoBR1 and Q-actin
may dampen the inflammatory response of blood/circulating
immune cells.
The inhibition of LPS-induced TNF-α production in ex vivo
human blood was strong (50% inhibition at 0.1 μM for idoBR1
in blood) when there was preincubation with the compound or
extract (50% reduction at ca. 1 mg/mL. of extract with >1%
idoBR1 (equating to >56 μM idoBR1), confirming that
idoBR1 alone can be responsible for the anti-inflammatory
effect of cucumber extract). Preincubation of human plasma
with idoBR1 and Q-actin cucumber extract prior to LPS
stimulation for 20 h significantly reduced TNF-α levels.
Statistical significance was determined with one-way ANOVA.
Under similar incubation conditions used for the human
plasma study but using human THP-1 cells, the inhibitory
action of idoBR1 (at 10 μM) was comparable to that of
identical pretreatment with DM (50 μM) with an inhibition of
>50 and >65%, respectively. Mifepristone alone with LPS
greatly amplified TNF-α production from the THP-1 cells;
however, in the presence of DM, it reversed the suppressive
action of DM but not that of idoBR1. As mifepristone is
primarily a progesterone receptor antagonist, this indicates that
idoBR1 is unlikely to act via a glucocorticoid or progesterone
receptor. idoBR1 (10 μM) in the absence or presence of LPS
(10 μg/mL) did not reduce the viability of the THP-1 cells
and indeed may have had a small cytoprotective action,
especially in the presence of LPS.
Serum Cytokine Study in Healthy Humans Given
Cucumber Extract. The 4 day pilot study involving intense
periods of resistance exercise with consumption of cucumber
extract with 20 mg of 1.4% idoBR1 (iminosugar) or placebo 1
h prior to exercise showed a trend for cucumber extract
controlling inflammatory cytokines with TNF-α appearing to
be held fairly constant (Figure 4a), while IL-10 (Figure 4b)
and the Th-1 cytokine IL-12p70 (Figure 4c) showing a trend
to be increased on cucumber extract consumption combined
with intense exercise. Interestingly, IL-12p70 is considered
proinflammatory but has an important role in preventing
infections, for example, viruses.21,22
idoBR1 Reduces Sialidase Activity. DNJ is a potent
inhibitor of α- and β-glucosidases.19 To determine whether
idoBR1 was also a glycosidase inhibitor, assays were performed
to measure the effects of idoBR1 on a panel of glycosidases.
idoBR1 most potently, selectively, inhibited broad-specificity
bacterial sialidase (Table 1) with 60% inhibition at 0.8 mM
(IC50 0.5 mM; oseltamivir had an IC50 of 0.25 mM in the same
assay). Bacterial sialidase is a reported virulence factor that
contributes to inflammatory responses by modifying the
glycosylation status of toll-like receptors (as well as other
receptors involved in inflammation such as integrins and
EGFR).23 DNJ was not inhibitory to the same sialidase at 0.8
mM. idoBR1 was not strongly inhibitory to any of the other
glycosidases assayed, but it was weakly inhibitory to α-L-
iduronidase with an IC50 of approximately the concentration
tested (1.5 mM). As expected from Manning et al.,8 BR1 here
gave moderate inhibition of β-glucuronidase at the concen-
tration used; in contrast, DNJ was a potent inhibitor of Bacillus
but not yeast α-glucosidases and also showed significant
inhibition of β-glucosidase. These data show that idoBR1 and
BR1 are moderate glycosidase inhibitors but are selective in
their inhibition profiles. A further study looking at inhibition of
human sialidase activity induced in THP-1 cells treated with
LPS also showed an inhibitory effect (Figure 5). The standard
idoBR1 tested at 0.28 and 0.56 mM showed a maximum
reduction in relative sialidase activity of 0.63 and 0.55,
respectively, compared to the LPS control. Q-actin at 100
and 200 μg/mL showed a maximum reduction of relative
sialidase activity to 0.7 and 0.62, respectively, compared to the
control (LPS). The result of this study could be a combination
of reduced expression of sialidase or inhibition of the enzyme
by idoBR1.
Interestingly, an induced sialidase is proposed to be involved
in inflammatory responses mediated by CD44.24 CD44 has
been shown to be involved in hemopoiesis, homing to the
mucosal lymphatic tissue, and lymphocyte infiltration into
inflammatory tissues.25 HA interactions with CD44 and
CD168 (RHAMM) can induce numerous cell behaviors,
including activation of tyrosine kinases, protein kinase C, FAK,
Pi3K, mitogen-activated protein kinases (MAPK), NFκB, and
RAS, as well as cytoskeletal components required for
inflammation and cancer. Although most cells express some
Figure 4. (a) Mean serum before and after intense exercise TNF-α
was not increased in the subjects given cucumber extract (iminosugar)
1 h before exercise compared to the placebo group. (b) Mean before
and after intense exercise IL-10 serum levels in the cucumber extract
subjects (purple) compared to the placebo group (green). (c) Mean
before and after intense exercise IL-12p70 levels in the serum of those
given cucumber extract (purple) compared to those given the placebo
(green).
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form of CD44, not all cells constitutively bind to HA.26,27
Functionally active HA-adhesive CD44 is produced through
induction of sialidase via MAPK activation.
Studies carried out to understand the role of MAPK in the
LPS-induced inflammatory response show MAPK p42/44-
mediated TNF-α production and subsequent TNF-α-mediated
p38 activation, resulting in the production of HA-adhesive
CD44 by sialidase activity.28 Thus, a possible mechanism for
the anti-inflammatory activity of idoBR1 is via inhibition of an
induced sialidase, and this sialidase may interact directly with
inflammatory receptors such as TLRs.29
Investigations of Signaling Pathways Involving
idoBR1 and Q-Actin and Associated Levels of Inflam-
matory Markers in Cell-Based Assays. Next, we tested
whether isolated idoBR1 and the standardized cucumber
extract Q-actin, that contains >1% idoBR1, could reduce the
inflammatory response of LPS-stimulated human monocytes
(differentiated adherent macrophages and THP-1 cell-derived)
and studied signaling. Even with a fairly short incubation time
with LPS, the amount of released TNF-α was significantly
reduced from low to high concentrations of both idoBR1 and
Q-actin (Figure 6A). Concurrent with a reduction in TNF-α
levels is the reduction of a downstream signaling product of
TNF-α, the association of HA with the CD44 receptor (Figure
6F). The CD44 binding study which showed CD44-bound HA
was 110 ng/mL in the LPS-stimulated (1 μg/mL) THP-1 cell-
derived macrophages, whereas ido-BR1 at 100 μg/mL gave a
reduction of CD44-HA levels (27%) as compared to the LPS
control. Cucumber extract Q-actin at 200 μg/mL also gave a
reduction of CD44-HA levels (31%) in THP-1 cells as
compared to the LPS control. DM, the positive control, gave a
reduction of 24% at 100 ng/mL and 42% at 1000 ng/mL.
TNF-α can also synergize with other cytokines, notably
interleukin-1 (IL-1), to aggravate many inflammatory
responses.30,31 Therefore, we also analyzed the release of IL-
1α and IL-1β and found that idoBR1 significantly reduced
levels of both IL-1α and IL-1β from 25 to 100 μg/mL and Q-
actin from 50 to 100 μg/mL (Figure 6C,D). Similarly, a
significant reduction was observed for IL-12 release (note not
so in the humans given intense exercise over a longer period),
which acts to stimulate IFN-γ and TNF-α production in T
lymphocytes (Figure 6B). In addition to a reduction in the
production of proinflammatory cytokines, we also observed a
significant increase in the release of the anti-inflammatory
cytokine IL-10 at all concentrations of idoBR1 and from 25 to
100 μg/mL Q-actin (Figure 6E). These data suggest that
idoBR1 and Q-actin potentially reduce inflammatory responses
in LPS-stimulated human monocytes, perhaps by reducing the
activity of an induced sialidase involved in CD44-HA binding.
MAPK Signaling Effects of idoBR1 and Cucumber
Extract Containing idoBR1. MAPK signaling cascade plays
an essential role in the initiation of inflammatory responses.
The induction of inflammatory cytokine genes requires
activation of the MAPKs and stimulation of extracellular
regulated protein kinase/MAPK (ERK/MAPK) pathways
essential for downstream inflammatory responses.32,33 The
MAPK pathway is also required for the expression of
inflammatory mediator genes, including COX-2, iNOS, IL-
1β, and TNF-α. It was reported that the ERK and/or p38
MAPK are involved in upregulation of IL-1β.34 Q-actin tested
at 100 and 200 μg/mL showed relative reduction in
phosphorylated p38 expression of 0.92 and 0.83, respectively,
compared to the LPS control. In the case of idoBR1 at 50 and
100 μg/mL, it showed reductions in phosphorylated p38
expression of 0.88 and 0.80, respectively, compared to the LPS
control. Q-actin tested at 100 and 200 μg/mL showed relative
reductions in phosphorylated ERK 42/44 expression of 0.81
and 0.78, respectively, compared to the LPS control (Tables 2
and 3). idoBR1 at 50 and 100 μg/mL showed reductions in
phosphorylated ERK 42/44 expression of 0.80 and 0.76,
respectively, compared to the LPS control. Both idoBR1 and
cucumber extract containing idoBR1 (Q-actin) are, therefore,
shown to be able to reduce the MAPK signaling cascade that
plays an essential role in the inflammatory response.
Table 1. Comparison of the Glycosidase Inhibitions (% Inhibition) by idoBR1, BR1, and DNJa
enzyme source % inhib. by idoBR1 (1) % inhib. by BR1 (2) % inhib. by DNJ (3)
α-D-glucosidase Saccharomyces cerevisiae 0 0 36
α-D-glucosidase Bacillus sterothermophilus 26 49 100 (IC50 2.6 μM)
β-D-glucosidase almond 0 7 64
α-D-galactosidase green coffee bean 0 0 0
β-D-galactosidase bovine liver 0 0 0
α-D-mannosidase jack bean −28 29 27
β-D-mannosidase Cellullomonas fimi 0 8 −19
N-acetyl-β-D-glucosaminidase bovine kidney 0 0 0
N-acetyl-β-D-glucosaminidase jack bean 0 10 0
β-D-glucuronidase bovine liver 0 89 ND
α-L-iduronidase recombinant human 48 9 ND
sialidase T. forsythia 60 (IC50 0.5 mM) ND ND
aND = not determined. All compounds were assayed at 0.8 mM (except for 1.4 mM for iduronidase). Negative values show promotion of the
enzyme activity.
Figure 5. Sialidase inhibition by idoBR1 following LPS stimulation in
THP-1 cells. Sialidase activity was significantly reduced in cells treated
with idoBR1 in the presence of LPS at both concentrations. Statistical
significance determined by two-way ANOVA.
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The results show that idoBR1 gives inhibition of sialidases
from both bacteria and human THP-1 cell cultures. Q-actin
cucumber extract with >1% idoBR1 was also shown to inhibit
the human cell sialidase activity.
Oral Fate of idoBR1 in Humans. Finally, we conducted a
pilot experiment to determine if by oral route idoBR1 was
excreted largely unmetabolized in urine as other iminosugars
studied previously in rats.35−37 Two adults consumed 1 g of Q-
actin in water, calculated to contain 14 mg of idoBR1. idoBR1
was clearly seen by GCMS in the urine. After 15 h, the male
showed excretion of approximately 6 mg of idoBR1 compared
to the castanospermine reference peak area. The female had
excreted approximately 9 mg of idoBR1 in 9 h. It is reported in
rats that less than 50% DNJ, fagomine, and 1,4-dideoxy-1,4-
imino-D-arabinitol37,38 are excreted in urine, although a more
accurate 15N-labeled DNJ study reports 80% excretion by rats
over 48 h,24 and the authors conclude it may take longer than
48 h to be completely eliminated. Our method using cation
Figure 6. idoBR1 reduces LPS-induced increase in proinflammatory cytokine release in human monocytes. THP-1 cells were stimulated with LPS
in conjunction with the anti-inflammatory steroid analogue, DM, idoBR1, or Q-actin and assessed for cytokine release following 2 h incubation.
(A,B) TNF-α and IL-12 levels were elevated in the presence of LPS and significantly reduced by DM and at all concentrations of idoBR1 and Q-
actin. (C,D) IL-1α and IL-1β levels were elevated by LPS and significantly reduced by DM. idoBR1 treatment shows significant reduction at 25−
100 μg/mL, and Q-actin significantly reduced levels at 50−100 μg/mL concentrations; (E) anti-inflammatory IL-10 was significantly increased in
DM and all concentrations of idoBR1 and Q-actin; (F) CD44-HA binding activity was significantly reduced in DM, all idoBR1, and at 25−100 μg/
mL Q-actin concentrations. Statistical significance was determined with one-way ANOVA.
Table 2. Relative Expression of p42/44
test samples conc. (μg/mL) relative expression
LPS 1 1.00
Q-actin 100 0.81
Q-actin 200 0.78
idoBR1 50 0.80
idoBR1 100 0.76
DM 1 0.65
Table 3. Relative Expression of p38
test samples conc. (μg/mL) relative expression
LPS 1 1.00
Q-actin 100 0.92
Q-actin 200 0.83
idoBR1 50 0.88
idoBR1 100 0.80
DM 1 0.54
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exchange chromatography gave a useful concentration step that
allowed clear identification of idoBR1 in human urine that
would allow a more detailed availability and elimination study.
It does appear though that idoBR1 is orally stable in humans
and is largely excreted in urine over several hours. Anti-TNF
therapies such as etanercept and infliximab show great promise
against even intractable diseases such as Crohn’s disease, but
immune response to these proteins severely limits their
prolonged use;39 idoBR1 or Q-actin may therefore have
some advantages over these existing treatments.
In conclusion, idoBR1 in certain cucumbers has an anti-
inflammatory activity that may be due to sialidase inhibition or
interaction with CD44-HA signaling. Regular consumption of
cucumbers with idoBR1 may have a significant effect, as
suggested by the effect of preincubation on TNF-α production
in human plasma. Long-term use of steroids is not
recommended,40 and commonly used nonsteroidal anti-
inflammatory drugs can also have several negative effects,
including effects on the central nervous system.41 idoBR1 is a
nonsteroid and appears to have a novel mechanism. It appears
nontoxic to humans, although its health significance in the diet
should be studied further.
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